Arteriovenous Fistula Devices Market Size, Share, Opportunities, And Trends By Type (AVF Creation Devices, AVF Monitoring Devices, AVF Maintenance Devices), By End-Use (Hospitals, Ambulatory Surgical Centers, Dialysis Centers), By Distribution Channel (Online, Offline), And By Geography - Forecasts From 2023 To 2028

The arteriovenous fistula devices market is estimated to grow at a CAGR of 7.61% during the forecast period.

AVF devices are chosen over alternatives such as catheters or arteriovenous grafts for vascular access because of their longevity, decreased risk of infection, and better long-term results. These tools are essential for helping ESRD patients obtain vascular access and allowing successful hemodialysis treatments. For instance, hemodialysis, which accounts for roughly 69% of all kidney replacement treatment and 89% of all dialysis operations, is the most used kind of kidney replacement therapy globally.

Growth drivers for the arteriovenous fistula devices market

Arteriovenous fistula (AVF) devices are produced to give dependable vascular access for dialysis treatments, and this has led to an increase in the prevalence of ESRD, which requires hemodialysis. The need for AVF devices has also been spurred by improvements in minimally invasive treatments including endovascular methods and embolization.

To increase their market domination, major firms in the arteriovenous fistula devices market are continually executing strategic initiatives, such as mergers, acquisitions, partnerships, and intense R&D work. Through these measures, the companies hope to improve their product lines, increase their market share, and promote advancements in AVF device technology.

High prevalence of end-stage renal disease

The arteriovenous fistula devices industry is anticipated to expand due to a variety of factors, including the rising incidence of end-stage renal disease (ESRD) and the consequent increase in the number of patients needing hemodialysis. A total of 786,000 Americans are estimated to have end-stage renal disease (ESRD) or end-stage kidney disease (ESKD), according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). In this group, 71% are on dialysis, while the remaining 29% have had kidney transplants.

Growing demand for advanced treatment methods

The market for treating arteriovenous fistulas is anticipated to grow throughout the anticipated period as companies create innovative sclerotherapy techniques such as photodynamic therapy and antiangiogenic therapy. Players are motivated to create cutting-edge treatment technologies since the ideal therapy for a quick and complete recovery is still being developed. Additionally, increasing FDA approvals of noninvasive devices for creating arteriovenous fistulas have contributed to the arteriovenous fistula devices industry expansion throughout the anticipated period.

A self-generated arteriovenous fistula is also acknowledged to be the best access for hemodialysis transmission. On the other side, the surgical formation of an arteriovenous fistula is a sign of subpar technical performance, and many treatments are sometimes needed to promote maturation or maintain early patency.

Increasing utilization of AVF creation devices

The prevalence of ESRD is rising, and more people need dialysis therapy than ever before, which has increased the demand for AVF creation devices. By facilitating efficient vascular access, boosting patient care, and raising patient quality of life, AVF creation devices are essential in addressing the rising demand for dialysis therapy.

The arteriovenous fistula devices market is expanding as a result of the introduction of innovative products by key companies that speed up the AVF process. These ground-breaking approaches are meticulously crafted to streamline and optimize the production of AVFs, resulting in increased success rates and general development of the sector. For instance, the Ellipsys Vascular Access System from Medtronic can expand the number of professionals who perform vascular access treatments.

Use of AVF devices in hospitals

Particularly in the context of hemodialysis treatments, hospitals are a key factor in the arteriovenous fistula devices market growth. Three hemodialysis treatments are typically covered by Medicare and the majority of other health insurance plans in the United States each week. Because of this coverage, hospitals can undertake a variety of AVF-required hemodialysis operations. A larger hospital requirement for AVF devices is brought about by the rising demand for hemodialysis treatments, which is supported by insurance coverage. As a consequence, the hospital sector is a significant factor in boosting arteriovenous fistula device market growth.

Arteriovenous fistula devices are expected to see the fastest growth in North America.

Kidney disease is a major health concern in North America, and AVF devices are essential for supplying hemodialysis patients with vascular access. The regional arteriovenous fistula devices market is expanding as a result of the increasing demand for AVF treatments and the focus on patient outcomes. The American Kidney Fund, Inc. claims that kidney illness is becoming more and more common, which is a worrying trend. For instance, more than 15% of American adults, or more than one in seven people, suffer from renal illness. These factors are the key reason propelling the arteriovenous fistula devices market in North America.

Arteriovenous Fistula Devices

• Ellipsys Vascular Access System, the EllipsysTM system is a one-catheter, nonsurgical method for doctors to establish an arteriovenous (AV) fistula, before the development of percutaneous AVF technology, only available to patients with end-stage renal disease (ESRD) who needed hemodialysis.
• VasQ Device, the VasQ device offers a ground-breaking method of treating AV fistulas. A subcutaneous arteriovenous conduit for vascular access is the VasQ device. It is a channel support that is externally used exclusively with brachiocephalic or radiocephalic AVF.
• AMPLIFI vein dilation system, launched by Artio Medical is a wearable external blood pump that generates fast, non-pulsatile blood flow to pre-dilate draining veins. It has inflow and outflow catheters. This device is intended to be worn for 14 days before the formation of an AVF.

Market Key Developments

• In January 2023,  Alucent Biomedical Inc. created and marketed its cutting-edge AlucentNVS technology for the treatment of vascular diseases.
• In May 2022, to reduce the danger of arteriovenous fistula failure, Laminate Medical offers external support for a patient's vasculature. Alio Smartwatch allows for remote patient monitoring of AV access flow surveillance.
• In March 2022, to encourage development into useful access for hemodialysis, the VasQ device is being implanted around the vein-artery junction of an AVF.

Arteriovenous Fistula Devices Market Scope:

Segmentation:

• By Type
  • AVF Creation Devices
  • AVF Monitoring Devices
  • AVF Maintenance Devices
• By End-Use
  • Hospitals
  • Ambulatory Surgical Centers
  • Dialysis Centers
• By Distribution Channel
  • Online
  • Offline
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Israel
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Thailand
    • Others